α2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 10, 2012, Pages

  Hsing, Chung Hsi ^a,d   Lin, Chiou Feng ^b   So, Edmund ^a   Sun, Ding Ping ^a   Chen, Tai Chi ^a   Li, Chien Feng ^a   Yeh, Ching Hua ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute kidney injury; Bone morphogenetic protein 7; Dexmedetomidine; Histone deacetylase 2; Histone deacetylase 5; Sepsis

Indexed keywords

DEXMEDETOMIDINE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; HISTONE H3; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOGENIC PROTEIN 1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; YOHIMBINE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; IN VITRO STUDY; KIDNEY TUBULE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RNA INTERFERENCE; SEPSIS; SEPTIC ACUTE KIDNEY INJURY; SURVIVAL;

EID: 84869183858     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00143.2012     Document Type: Article

References (53)

1. Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol 23: 361-372, 2006.
2. Billings IV FT, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT. α2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 295: F741-F748, 2008.
3. Chan WL, Leung JC, Chan LY, Tam KY, Tang SC, Lai KN. BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int 74: 1026-1039, 2008.
4. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology 76: 948-952, 1992.
5. Dahmani S, Rouelle D, Gressens P, Mantz J. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 103: 969-977, 2005.
6. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17: 1503-1520, 2006.
7. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619, 2005.
8. Elenkov IJ, Hasko G, Kovacs KJ, Vizi ES. Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha-and beta-adrenergic drugs in mice. J Neuroimmunol 61: 123-131, 1995
9. Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR, Sladen RN. Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth 18: 422-426, 2006.
10. Galley HF. Mice men, and medicine. Br J Anaesth 105: 396-400, 2010.
11. Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61: 51-60, 2002.
12. Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, Xia P, Maze M, Ma D. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice (Abstract). Crit Care 15: R153, 2011.
13. Hasko G, Elenkov IJ, Kvetan V, Vizi ES. Differential effect of selective block of α2-adrenoreceptors on plasma levels of tumour necrosis factoralpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol 144: 457-462, 1995.
14. Helder MN, Ozkaynak E, Sampath KT, Luyten FP, Latin V, Oppermann H, Vukicevic S. Expression pattern of osteogenic protein-1 (bone morphogenetic protein-7) in human and mouse development. J Histochem Cytochem 43: 1035-1044, 1995.
15. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589, 2003
16. Hofer S, Steppan J, Wagner T, Funke B, Lichtenstern C, Martin E, Graf BM, Bierhaus A, Weigand MA. Central sympatholytics prolong survival in experimental sepsis. Crit Care 13: R11, 2009.
17. Hsing CH, Chou W, Wang JJ, Chen HW, Yeh CH. Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsisinduced acute kidney injury. Nephrol Dial Transplant 26: 1162-1172, 2011
18. Kadoi Y, Saito S, Kawauchi C, Hinohara H, Kunimoto F. Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock. Br J Anaesth 100: 224-229, 2008
19. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl S105-S112, 2003.
20. Komaki M, Asakura A, Rudnicki MA, Sodek J, Cheifetz S. MyoD enhances BMP7-induced osteogenic differentiation of myogenic cell cultures. J Cell Sci 117: 1457-1468, 2004.
21. Kulka PJ, Tryba M, Zenz M. Preoperative α2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 24: 947-952, 1996
22. Kumar V, Sharma A. Is neuroimmunomodulation a future therapeutic approach for sepsis? Int Immunopharmacol 10: 9-17, 2010.
23. Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 13: 417-422, 2004.
24. Lin Y, Zhu X, Yao WZ, Yang YL, Chen L. Yohimbine protects against endotoxin-induced acute lung injury by blockade of α2A adrenergic receptor in rats. Chin Med J (Engl) 124: 1069-1074, 2011.
25. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the α2A-adrenoceptor subtype. Eur J Pharmacol 502: 87-97, 2004
26. Maric I, Poljak L, Zoricic S, Bobinac D, Bosukonda D, Sampath KT, Vukicevic S. Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol 196: 258-264, 2003.
27. Marumo T, Hishikawa K, Yoshikawa M, Fujita T. Epigenetic regulation of BMP7 in the regenerative response to ischemia. J Am Soc Nephrol 19: 1311-1320, 2008.
28. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T. Histone deacetylase modulates the proinflammatory and fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298: F133-F141, 2010.
29. Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, Himmelfarb J. Sepsis as a cause and consequence of acute kidney injury: Program to improve care in acute renal disease. Intensive Care Med 37: 241-248, 2011.
30. Memis D, Hekimoglu S, Vatan I, Yandim T, Yuksel M, Sut N. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth 98: 550-552, 2007.
31. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552, 2003.
32. Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 64: 1620-1631, 2003.
33. N'Diaye EN, Brown EJ. The ubiquitin-related protein PLIC-1 regulates heterotrimeric G protein function through association with Gβγ. J Cell Biol 163: 1157-1165, 2003.
34. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867, 1999.
35. Nishina K, Akamatsu H, Mikawa K, Shiga M, Maekawa N, Obara H, Niwa Y. The effects of clonidine and dexmedetomidine on human neutrophil functions. Anesth Analg 88: 452-458, 1999.
36. Ortiz-Arduan A, Danoff TM, Kalluri R, Gonzalez-Cuadrado S, Karp SL, Elkon K, Egido J, Neilson EG. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1193-F1201, 1996.
37. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 335: 266-272, 2010.
38. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K, De Bleser P, Yoshida M, Schuppan D, Rojkind M, Geerts A. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-β(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 278: 184-197, 2002.
39. Rouch AJ, Kudo LH, Hebert C. Dexmedetomidine inhibits osmotic water permeability in the rat cortical collecting duct. J Pharmacol Exp Ther 281: 62-69, 1997.
40. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 54: 710-716, 2010.
41. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M. Dexmedetomidine attenuates isofluraneinduced neurocognitive impairment in neonatal rats. Anesthesiology 110: 1077-1085, 2009.
42. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 351: 159-169, 2004.
43. Song XM, Wang YL, Li JG, Wang CY, Zhou Q, Zhang ZZ, Liang H. Effects of propofol on pro-inflammatory cytokines and nuclear factor κB during polymicrobial sepsis in rats. Mol Biol Rep 36: 2345-2351, 2009.
44. Spiegelberg BD, Hamm HE. G βγ binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. J Biol Chem 280: 41769-41776, 2005.
45. Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 32: 1322-1326, 2004.
46. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 290: R861-R870, 2006.
47. Vizi ES, Orso E, Osipenko ON, Hasko G, Elenkov IJ. Neurochemical, electrophysiological and immunocytochemical evidence for a noradrenergic link between the sympathetic nervous system and thymocytes. Neuroscience 68: 1263-1276, 1995.
48. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102: 202-214, 1998.
49. Vukicevic S, Kopp JB, Luyten FP, Sampath TK. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci USA 93: 9021-9026, 1996.
50. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12: 2392-2399, 2001
51. Wetzel P, Haag J, Campean V, Goldschmeding R, Atalla A, Amann K, Aigner T. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int 70: 717-723, 2006.
52. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007.
53. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, Kalluri R. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 285: F1060-F1067, 2003.